TapImmune Releases Positive Interim Data for Ovarian & Breast Cancer
TapImmune Inc. is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
The trial is fully accrued and as of August 26, 2014, all 22 patients had completed their vaccinations. Eight women with HER2-negative breast cancer, 13 with ovarian cancer and one with fallopian tube cancer were enrolled.
Glynn Wilson, TapImmune’s CEO, stated “In general, the vaccine has been well tolerated. This is the first positive endpoint we have reported for the clinical study on folate receptor alpha antigens and when taken together, the promising data on safety and immune responses are tremendously encouraging and provide a clear scientific rationale for progressing to a Phase II Clinical Trial In addition to the primary Ovarian indication, this set of antigens and our approach fills a significant need for treatments for difficult to treat cancers for which targeted therapies are not available, for example Triple-negative breast cancer.”
The Phase I trial is being carried out at the Mayo Clinic, Rochester, MN. TapImmune has an Exclusive Option to License this antigen technology.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. For more information, visit www.tapimmune.com.
Total Page Views: 663
